Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-3

Agree. No mention of the clinical validation study. Yet we would seem that might tie in with first revenues.

"Commercial roll-out
Following the accreditation for our North Ryder laboratory from NATA, BCAL is in the final stages of
preparing for its regulatory approval for BREASTEST® and the first commercial site launch at the
Sydney Breast Clinic. The test will be offered alongside current screening methods and will begin
generating revenues for the Company by the end of Q1 CY25. During this time BCAL will secure
partnerships and licencing opportunities to bring BREASTEST® to as many women as possible."

So, pretty much saying high degree of confidence in conditions precedent to rollout.
And yet, the malaise in the sp, could be put down to the impatience, and perceived undertaking of the clinical trial.

From my perspective, when they have gathered the data from patients over many years to formulate the patents of lipid signatures, isnt a clinical trial, simply adding more of the same type patients against the underlying metric path to which they already traversed ?

Its like designing a shoe for cinderella, you measure her up, make the shoe, then you invite here back to try it on. What the market is saying today, is , of course Cinderella is almost ready for the ball, here are her designer shoes ready in a little while.